TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of changes in equity
| Teva shareholders' equity | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | ||||||||||||||||
| Number of shares (in millions) · Stated value · Additional paid-in capital · Retained earnings (accumulated deficit) · Accumulated other comprehensive income (loss) · Treasury shares · Total Teva shareholders' equity · Non-controlling interests · Total equity | ||||||||||||||||
| (U.S. dollars in millions) | ||||||||||||||||
| Balance at June 30, 2026 | 1,271 | $59 | $28,256 | $(13,969) | $(2,465) | $(4,128) | $7,753 | $4 | $7,757 | |||||||
| Net income (loss) | 233 | 233 | 1 | 234 | ||||||||||||
| Other comprehensive income (loss) | (91) | (91) | 1 | (90) | ||||||||||||
| Issuance of Shares | * | * | * | |||||||||||||
| Stock-based compensation expense | 38 | 38 | 38 | |||||||||||||
| Proceeds from exercise of options | 46 | 46 | 46 | |||||||||||||
| Reissuance of treasury shares for stock compensation plans | (31) | 31 | — | — | ||||||||||||
| Balance at September 30, 2026 | 1,272 | $59 | $28,309 | $(13,736) | $(2,556) | $(4,097) | $7,979 | $5 | $7,984 | |||||||
| Teva shareholders' equity | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | ||||||||||||||||
| Number of shares (in millions) · Stated value · Additional paid-in capital · Retained earnings (accumulated deficit) · Accumulated other comprehensive income (loss) · Treasury shares · Total Teva shareholders' equity · Non-controlling interests · Total equity | ||||||||||||||||
| (U.S. dollars in millions) | ||||||||||||||||
| Balance at December 31, 2025 | 1,257 | $58 | $28,133 | $(13,762) | $(2,391) | $(4,128) | $7,910 | $4 | $7,914 | |||||||
| Net income (loss) | 26 | 26 | 1 | 27 | ||||||||||||
| Other comprehensive income (loss) | (165) | (165) | 1 | (164) | ||||||||||||
| Issuance of shares | 15 | * | * | |||||||||||||
| Stock-based compensation expense | 121 | 121 | 121 | |||||||||||||
| Proceeds from exercise of options | 85 | 85 | 85 | |||||||||||||
| Reissuance of treasury shares for stock compensation plans | (31) | 31 | — | — | ||||||||||||
| Balance at September 30, 2026 | 1,272 | $59 | $28,309 | $(13,736) | $(2,556) | $(4,097) | $7,979 | $5 | $7,984 | |||||||
| Teva shareholders' equity | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||||||||
| Number of shares (in millions) · Stated value · Additional paid-in capital · Retained earnings (accumulated deficit) · Accumulated other comprehensive income (loss) · Treasury shares · Total Teva shareholders' equity · Non-controlling interests · Total equity | |||||||||||||||
| (U.S. dollars in millions) | |||||||||||||||
| Balance at June 30, 2025 | 1,253 | $58 | $28,003 | $(14,676) | $(2,431) | $(4,128) | $6,827 | $7 | $6,834 | ||||||
| Net income (loss) | 433 | 433 | 1 | 434 | |||||||||||
| Other comprehensive income (loss) | (44) | (44) | (44) | ||||||||||||
| Stock-based compensation expense | 34 | 34 | 34 | ||||||||||||
| Dividend to non-controlling interest* | (4) | (4) | |||||||||||||
| Balance at September 30, 2025 | 1,253 | $58 | $28,038 | $(14,243) | $(2,475) | $(4,128) | $7,250 | $4 | $7,254 | ||||||
- In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.
| Teva shareholders' equity | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||||||||||
| Number of shares (in millions) · Stated value · Additional paid-in capital · Retained earnings (accumulated deficit) · Accumulated other comprehensive income (loss) · Treasury shares · Total Teva shareholders' equity · Non-controlling interests · Total equity | |||||||||||||||||
| (U.S. dollars in millions) | |||||||||||||||||
| Balance at December 31, 2024 | 1,240 | $58 | $27,764 | $(15,173) | $(3,148) | $(4,128) | $5,373 | $7 | $5,380 | ||||||||
| Net income (loss) | 930 | 930 | 1 | 931 | |||||||||||||
| Other comprehensive income (loss) | 673 | 673 | 673 | ||||||||||||||
| Issuance of shares | 13 | * | * | ||||||||||||||
| Proceeds from exercise of options | 3 | 3 | 3 | ||||||||||||||
| Stock-based compensation expense | 106 | 106 | 106 | ||||||||||||||
| Purchase of shares from redeemable non-controlling interests** | 165 | 165 | 165 | ||||||||||||||
| Dividend to non-controlling interest*** | (4) | (4) | |||||||||||||||
| Balance at September 30, 2025 | 1,253 | $58 | $28,038 | $(14,243) | $(2,475) | $(4,128) | $7,250 | $4 | $7,254 | ||||||||
**In connection with the sale of Teva’s business venture in Japan.
***In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.